BGI Genomics Co (300676) Fair Value & Analysis
Healthcare · CN · Market cap 14.2B CNY
Fair value as of: Jul 24, 2026
From 2 valuation models · updated 17 days ago
Share price +15.4% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥22.97). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range ¥32.88 – ¥156.61 · fair‑value band ¥17.15 – ¥22.97 · the ¥39.96 price screens above the ¥20.06 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
BGI Genomics Co (300676) currently trades at ¥39.96, while our model-based Fair Value estimate is ¥20.06, implying the stock looks roughly 49.8% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, BGI Genomics Co generated revenue of 3.8B CNY at a net margin of -14.9%. Revenue grew 20.4% year over year. It earns a return on equity of -6.7%. The balance sheet holds a net cash position of 3.5B CNY. Fundamentals as of Jul 24, 2026
Our scenario range runs from ¥17.15 (bear case) to ¥22.97 (bull case); at ¥39.96, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -50%, 300676 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: Multiples (¥18.44) versus Asset-Based (¥13.60). Highest evidence: EV/EBITDA (54).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally.
Full company description
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions. In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BGI Genomics Co reported revenue of ¥3.7B in FY2025 versus ¥6.8B in FY2021, a compound −14.0%/yr. Reported net income was −¥617M in FY2025.
300676 screens 50% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare BGI Genomics Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BGI Genomics Co (300676) overvalued or undervalued?
What is the fair value of 300676?
What is the quality score of 300676?
What is the revenue of BGI Genomics Co (300676)?
What is the net profit margin of 300676?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BGI Genomics Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.